Oncology

#Academic #AI / data analytics / healthtech / informatics #Analysis #Automation / robotics #Biochemistry #Business #Cell therapy #Cellular & Molecular biology #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #High Content Screening #High throughput screening #Lead discovery #Oncology #Pathology #PCR #Pharmacology #Pharmokinetics #Preclinical #Regulatory #RNA #Screening #Stem cells #System biology #Systems biology #Target validation

The Apocalyptic Horsemen of Drug Discovery and Development

The Apocalyptic Horsemen of Drug Discovery and Development By Dr Gary J. Keil The pharmaceutical industry should consider an evolutionary disease management approach based on homeostasis, irreversibility, biological alinearity, pseudo-N-of-1 health and disease states and narrative medicine best practices in order to help secure a successful drug development future. The… Read More

#Archive

#Analysis #Assay development optimisation & technology #Biomarkers #Business #Drug development #Drug discovery #Enabling technologies #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #Immunology #Lead discovery #Metabolomics #Molecular medicine #Oncology #Precision medicine #System biology #Systems biology #Translational #Translational chemistry

Using autoantibody biomarker panels for improved disease diagnosis.

By Dr John Anson, Oxford Gene Technology Molecular biomarkers that define a particular state or condition are a powerful tool used to diagnose disease, highlight patients with a pre-disposition towards a given disease and to identify those who would benefit from a given therapy. Until now, most diagnostic tests have… Read More

#Archive

#AI / data analytics / healthtech / informatics #Biochemistry #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Chemistry #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #High Content Screening #Immunology #Lead discovery #Oncology #Pharmacology #Pharmokinetics #Preclinical #Protein chemistry / Proteomics #RNA #Therapeutics

SMAC Mimetics: a new class of targeted agents that activate apoptotic cell death and block pro-survival signalling in cancer cells

SMAC Mimetics: a new class of targeted agents that activate apoptotic cell death and block pro-survival signalling in cancer cells By Dr Mark A. McKinlay SMAC mimetics are a new class of targeted drugs being developed for the treatment of solid tumours and hematologic cancers. SMAC mimetics specifically induce apoptotic… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Biochemistry #Biomarkers #Cell therapy #Cellular & Molecular biology #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #High Content Screening #High throughput screening #Imaging #Lead discovery #Oncology #Pathology #Protein chemistry / Proteomics #RNA #Sequencing #Stem cells #Target validation #Therapeutics #Toxicology

Targeting Target Cancer Metabolism – What is fuelling the resurgence?

Targeting Target Cancer Metabolism - What is fuelling the resurgence? By Dr Neil P. Jones Targeting the metabolic pathways of cancer is a hot topic for drug discovery. The central dogma is that cancers have a higher demand for metabolic inputs to aid proliferation and survival and that this could… Read More

#Archive

#Analysis #Cell therapy #Cellular & Molecular biology #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #Genomics #Lead discovery #Molecular medicine #Oncology #Orphan drugs #Pathology #PCR #Protein chemistry / Proteomics #RNA #Stem cells #Target validation #Therapeutics #Translational #Translational chemistry

Present and Future Challenges in Type 2 Diabetes

By Dr Lesley J Millatt, Dr Rmy Hanf and Dr Dean W Hum According to the International Diabetes Federation, more than 285 million people (6.4% of the world population) are currently estimated to suffer from diabetes, a figure which is expected to rise to 438 million (7.8%) by 2030. Moreover,… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Biochemistry #Biomarkers #Business #Cell therapy #Clinical specialities #Clinical trials #Computational chemistry #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #High Content Screening #High throughput screening #Immunology #Lead discovery #Metabolomics #Molecular medicine #Oncology #Pharmacology #Precision medicine #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology #Translational #Translational chemistry

Early Patient Stratification is Critical to Enable Effective and Personalised Drug Discovery and Development

Early Patient Stratification is Critical to Enable Effective and Personalised Drug Discovery and Development By Dr David A Fryburg, Dr Diane H Song and Dr David de Graaf With the current chances of an efficacious outcome in Phase II for novel mechanisms being in the region of 1 in 5,… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Automation / robotics #Biomarkers #Business #Cellular & Molecular biology #Cellular assays #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomes #High Content Screening #Imaging #Lead discovery #Lead optimisation #Oncology #PCR #Pharmacology #Pharmokinetics #Preclinical #Protein chemistry / Proteomics #RNA #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Translational #Translational chemistry

In Vivo Preclinical Imaging – An Essential Tool in Translational Research

In Vivo Preclinical Imaging - An Essential Tool in Translational Research By Dr John Comley In vivo imaging of small animals (mainly mice) is increasingly being deployed across the drug development process, particularly in the oncology/cancer therapeutic area. One of the main applications is monitoring the treatment response for early… Read More

#Archive

#ADME / Tox #AI / data analytics / healthtech / informatics #Animal models #Assay development optimisation & technology #Cell / tissue culture #Cell culture #Cell therapy #Cellular assays #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Enabling technologies #Gene therapy #Genetics / genomes #High throughput screening #Lead discovery #Oncology #Preclinical #Protein chemistry / Proteomics #Regenerative Medicine #Regulatory #RNA #Screening #Stem cells #Therapeutics #Toxicology

Enabling the Promise of Stem Cells

Enabling the Promise of Stem Cells By Robert Shaw and Dr Jeff Till The remarkable potential of stem cells to generate several hundred differentiated cell types is driving their use for regenerative medicine and for supporting the traditional drug discovery and development process (Figure 1). However, sustained progress in these… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biomarkers #Business #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene editing #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High throughput screening #Lead discovery #Oncology #Orphan drugs #PCR #Precision medicine #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Target validation #Translational #Translational chemistry

The Post Genomic Era: What Does It All Mean?

The Post Genomic Era: What Does It All Mean? By Dr Chris Torrance Information may no longer be a bottleneck to understanding and tackling complex genetic diseases such as cancer. For those who cut their research teeth not so very long ago, before PCR was thought of by Kary Mullis,… Read More

#Archive

#Analysis #Animal models #Assay development optimisation & technology #Biologics / Biotechnology #Business #Cell therapy #Cellular assays #Clinical specialities #Clinical trials #Drug development #Drug discovery #Enabling technologies #Gene therapy #High Content Screening #Lead discovery #Oncology #Patent Law #Regenerative Medicine #Regulatory #RNA #Screening #Stem cells

Regenerative Medicines: A Paradigm Shift in Healthcare

By Michael Werner, Morrie Ruffin and Elizabeth West The regenerative medicine market offers phenomenal opportunities for growth in the next few decades. However, there are still major issues to be addressed to enable this nascent industry to truly flourish, especially with regard to investment and the attitudes of regulatory agencies… Read More

#Archive

#Academic #Analysis #Assay development & optimisation #Assay development optimisation & technology #Biochemistry #Biomarkers #Business #Cell therapy #Cellular assays #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Gene therapy #Genetics / genomes #Genomics #High Content Screening #Imaging #Immunology / Virology & Vaccines #Lead discovery #Mass spectrometry / NMR #Molecular medicine #Oncology #Pathology #Pharmacogenomics #RNA #Screening #Sequencing #Therapeutics

The Future of Molecular Diagnostics For Cancer: A Personalised Approach

By Dr Cliff Murray Drug Discovery The pharmaceutical industry is still struggling to cure cancer despite pouring enormous resources into the search for new treatments. We take a look at the some of the current technologies for the discovery and delivery of molecular diagnostic, prognostic and predictive tests and speculate… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Biochemistry #Business #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Drug development #Drug discovery #Drug targets #Enabling technologies #Flow Cytometry #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Immunology #Lead discovery #Lead optimisation #Mass spectrometry / NMR #Oncology #PCR #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology #Translational #Translational chemistry #Urinary

Epigenetics: An Emerging Target Class for Drug Screening

Epigenetics: An Emerging Target Class for Drug Screening By Dr John Comley Heightened awareness of the potential importance of epigenetic targets in many disease areas, and growing vendor interest in developing new assays to screen DNA methylation and histone modifications encouraged HTStec to undertake market research in this area in… Read More

#Archive

#Automation / robotics #Biologics / Biotechnology #Business #Cell therapy #Cellular & Molecular biology #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #Immunology #Lead discovery #Oncology #Pharmokinetics #Regulatory #RNA

Balancing A Biologics Pipeline Portfolio

Balancing A Biologics Pipeline Portfolio By Dr Herren Wu Research into groundbreaking biologic therapies has significantly shifted the diagnosis and treatment paradigms for many disease categories, particularly in oncology, autoimmune, inflammation and neurology. Discovering and developing an innovative, first-in-class biologic has the potential to offer patients significant benefits as well… Read More

#Archive

#Business #Clinical specialities #Clinical trials #Drug development #Oncology #Orphan drugs #Regulatory

Making Early Access Real: getting treatments to patients with no other option

Making Early Access Real: getting treatments to patients with no other option By Dr Rav Seeruthun For patients who have no other option to treat their condition, early access to drugs in clinical development can be critical. As a trained physician, there is an intrinsic understanding that early access to… Read More

#Archive

#Academic #Analysis #Analytical chemistry #Animal models #Assay development optimisation & technology #Automation / robotics #Biomarkers #Business #Cell therapy #Cellular assays #Chemical engineering #Chemistry #Clinical trials #Drug development #Drug discovery #Enabling technologies #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #Mass spectrometry / NMR #Molecular medicine #Oncology #Pharmacology #Precision medicine #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #System biology #Target validation #Translational #Translational chemistry

Protein Biomarker Immunoassays: Opportunities and Challenges

Protein Biomarker Immunoassays: Opportunities and Challenges By Dr M. Walid Qoronfleh and Dr Klaus Lindpaintner With the biopharma industry under heavy pressure, transforming the scientific interchange between the laboratory and the clinic is exceedingly critical. Realising the costly toll of drug attrition in late-stage development, many companies are turning to… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Biologics / Biotechnology #Cell therapy #Clinical specialities #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #High throughput screening #Immunology #Oncology #PCR #Preclinical #RNA #Screening #Stem cells #Therapeutics #Toxicology

New Ways to Optimise Therapeutic and Diagnostic Antibodies

New Ways to Optimise Therapeutic and Diagnostic Antibodies By Dr Markus Enzelberger Monoclonal antibodies are the fastest-growing category of research within the biotech and pharmaceutical industries. Several monoclonal antibodies are listed in the top 10 selling blockbusters, and the market forecast predicts that the number of monoclonal antibodies within the… Read More

#Archive